UnitedHealth flags challenges in Medicare obesity drug pilot

HealthInternationalUnitedHealth flags challenges in Medicare obesity drug pilotBy Reuters -Apr 22, 2026UnitedHealth said on Tuesday there are “challenges” around the Medicare pilot program to cover obesity drugs, adding uncertainty over whether ​health insurers would sign up for it. Under the program called Balance, ‌the US Centers for Medicare and Medicaid Services will set standardized coverage terms by directly negotiating guaranteed net prices, potentially capping out-of-pocket costs for GLP-1 drugs from Eli Lilly ​and Novo Nordisk. “There are some notable challenges and outstanding questions with ​the currently planned structure,” said UnitedHealth’s chief of government programs Bobby ⁠Hunter during the company’s first-quarter conference call, adding that the company is ​in active dialogue with the agency. The program, a focus for the Trump administration, ​had a Monday, April 20 deadline for health insurers to opt in. The agency said it will roll out a Medicare GLP-1 payment demo in July as a short-term bridge to ​the BALANCE program, letting beneficiaries access the drugs at administration-negotiated prices. UnitedHealth said ​it would participate in the demo. Bloomberg News, citing a spokesperson, said CVS Health, parent of ‌the ⁠major Medicare insurer Aetna, declined to participate in the obesity coverage program. Eli Lilly shares fell nearly 2%, while U.S.-listed Novo Nordisk shares were down 3.4%. Plans have long been vocal about their concerns with the model and unlikeliness to opt ​in due to various ​uncertainties, said TD ⁠Cowen analyst Molly Turco. US President Donald Trump signed a deal in November with Lilly and Novo to slash the ​prices of popular GLP-1 weight-loss drugs for the government’s Medicare ​and ⁠Medicaid programs, as well as for cash payers. “It’s clear open negotiation is a proven tactic embraced by the Trump administration and we’re not surprised managed-care providers are ⁠taking to ​the public forum as well,” said Citi ​analyst Geoff...